HEADER MENU PfizerPro.com Terveydentukena.fi For the media Take contact Search SEARCH PFIZER PRODUCTS RESEARCH RESPONSIBILITY CURRENT AFFAIRS RELEASES 04/08/2021 - Survey: Less than 40% of people over the age of 60 monitor their health regularly - Pulse is measured even more lazily, says the People's Movement 14/06/2021 - Pfizer Announces Financial Benefits Paid to Healthcare Professionals and Organizations 17/05/2021 - Survey: It can take years to get a diagnosis of psoriatic arthritis 06/05/2021 - The prevalence of ticks is determined with the help of a citizen survey - Punkkilive.fi is an observation site open to everyone 07/04/2021 - Record number of TBE cases in 2020 - Growth possibly driven by climate change and camping boom 22/12/2020 - Pfizer and BioNTech's COVID-19 vaccine receives conditional marketing authorization from European Commission 30/09/2020 - Deb Mangone appointed Pfizer's new CEO in Finland 09/09/2020 - Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine candidate against COVID-19 08/09/2020 - Pfizer and BioNTech Advance to Selected COVID-19 Vaccine in Phase 2/3 Study in Germany 28/08/2020 - Pulse measurement is a new People's Movement - It can save more and more from a stroke 28/07/2020 - Pfizer and BioNTech Advance to Phase 2/3 Global Study with Selected COVID-19 Vaccine Candidate 15/06/2020 - Pfizer Announces Financial Benefits Paid to Healthcare Professionals and Organizations 19/05/2020 - SidekickHealth and Pfizer Finland launch digital service to support everyday well-being for people with inflammatory bowel disease 07/05/2020 - Pfizer and BioNTech's COVID-19 Vaccine Cases Advance to Phase I Clinical Trials in the United States 04/02/2020 - European Commission approves avelumab (Bavencio®) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma 29/01/2020 - Kyselytutkimus: suomalaislääkäreiden mielestä vastuu aikuisiän rokotuksista tulisi olla aikuisella itsellään, suurimpana haasteena on kuitenkin yksilön tiedonpuute 13/11/2019 - OIKAISU: Antibioottireseptit vähenevät Suomessa: toimitettujen antibioottireseptiostojen määrä laskenut vuosikymmenessä 29 % 12/09/2019 - Tuore tutkimustulos: Kotiin postitettu kirje kannustaa iäkästä ottamaan influenssarokotteen – rokotuskattavuus keskimäärin 7,7 prosenttiyksikköä parempi kuin vertailualueilla 13/06/2019 - Pfizer julkisti terveydenhuollon ammattilaisille ja organisaatioille maksetut taloudelliset etuudet 12/06/2019 - Pfizer Suomi ja Popit aloittavat yhteistyön potilaiden hoitoon sitoutumisen parantamiseksi 23/05/2019 - Survey: Doctors believe that drug treatments are becoming more individualized 06/05/2019 - Atrial fibrillation revealed by pulse - more than a quarter of Finns who respond to the survey do not feel any symptoms 16/01/2019 - HUS Cancer Center and Pfizer Collaborate to Promote Clinical Trials on Cancer Drugs Blogs Releases Research: Less than 40% of people over the age of 60 monitor their health regularly - Pulse is measured even more lazily, says the People's Movement Pfizer disclosed financial benefits paid to healthcare professionals and organizations Survey: It can take years to get a diagnosis of psoriatic arthritis The prevalence of ticks is determined with the help of a citizen survey - Punkkilive.fi is an observation site open to everyone Record number of TBE cases in 2020 - Growth possibly driven by climate change and camping boom Pfizer and BioNTech's COVID-19 vaccine has received a conditional marketing authorization from the European Commission Deb Mangone appointed Pfizer's new CEO in Finland Pfizer and BioNTech to supply 200 million doses of mRNA-based vaccine candidate for COVID-19 to the EU News MAIN NAVIGATION PFIZER New innovations for better health Pfizer is active in Finland Values and corporate culture Ura Pfizerilla History of Pfizer Pfizer Finland websites and social media channels Information for producers of goods and services PRODUCTS Pfizer brings hope with a selection of about 100 drugs Product list Pharmacovigilance Medicine package Counterfeit medicines are a health risk Logistics and availability of medicines Information on biological drugs and biosimilars TUTKIMUS Pfizer tutkii ja kehittää uusia lääkkeitä Uuden lääkkeen synty Tutkimustoiminta Suomessa Uusia lääkeinnovaatioita tehdään entistä useammin yhteistyössä Terveydenhuollon rekisterit tutkimuskäytössä Geeniterapia harvinaissairauksien hoidossa Terveytesi tähdet VASTUULLISUUS Pfizer vaikuttaa yhteiskunnassa Sidosryhmäyhteistyö Pfocus-foorumi Eettisyys Hyväntekeväisyys Suomessa ja maailmalla AJANKOHTAISTA Blogit Tiedotteet Uutiset MISCELLANEOUS PFIZERPRO TERVEYDEN TUKENA OTA YHTEYTTÄ ILMOITA HAITTAVAIKUTUKSESTA VERKKOPALVELUN KÄYTTÖEHDOT SOSIAALISEN MEDIAN KANAVIEN KÄYTTÖEHDOT YKSITYISYYTTÄ KOSKEVAT PERIAATTEET EVÄSTEIDEN KÄYTTÖ SOCIAL LINKS TWITTER FACEBOOK YOUTUBE INSTAGRAM ILMOITTAMINEN HAITTAVAIKUTUKSESTA If you would like to report an adverse reaction to a Pfizer product, please submit your report using the Report Abuse form or by calling +358 (0) 9 430 040. © Pfizer Ltd. 2021 All rights reserved. Labels for products listed on the site may vary by country. We need your consent to proceed We use cookies to enhance your website experience. We use necessary cookies to ensure our website functions properly and to keep it secure. These always need to be on. We use analytics cookies to measure website use, to learn what content is most useful to users and to help us improve it. We use marketing cookies to help us share content with you that you may find interesting and relevant. We use personalisation cookies to help manage your preferences and remember your settings. For more information see our Cookie Notice. Manage PreferencesDecline AllAccept All